Immuneering Corp (IMRX) — Institutional Holders, Q2 2026 (page 2)

112 institutional investment managers reported a IMRX position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $171.7M. Every filer is listed below, ranked by position value, 100 per page; this page shows ranks 101 to 112. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.

IMRX 13F holders ranked 101–112 of 112

Institutional investors reporting a position in Immuneering Corp on SEC Form 13F-HR for Q2 2026, ranked by reported value.
InstitutionValueQoQ
Tower Research Capital (TRC)#101 · 2,672 sh$13.3K-47.2%
GF FUND MANAGEMENT LTD.#102 · 1,341 sh$6.7K-7.0%
Sterling Capital Management#103 · 1,081 sh$5.4KNew
Union Bankshares#104 · 785 sh$3.9KNew
EverSource Wealth Advisors#105 · 345 sh$1.7K-32.9%
PRIVATE NA#106 · 250 sh$1.2KNew
ROTHSCHILD INVESTMENT#107 · 250 sh$1.2KNew
Geneos Wealth Management#108 · 200 sh$998.00New
Quarry#109 · 146 sh$729.00New
JONES FINANCIAL COMPANIES LLLP#110 · 30 sh$143.000.0%
OSAIC#111 · 18 sh$90.00+350.0%
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM#112 · 738 sh—New

Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.